CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 86 enrolled
Drug / intervention
Hyperbaric Oxygen Therapydevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05088772
NCT05088772N/ACompleted
CompareCT.gov

Pulmonary Function Following Hyperbaric Oxygen Therapy: A Prospective Cohort Study

University of Toronto·observational·Posted Oct 22, 2021·Updated May 16, 2024

In Brief

An observational study evaluating Hyperbaric Oxygen Therapy for Oxygen Toxicity. Completed, enrolled 86 participants across 1 site.

Detailed Summary

Patients receiving hyperbaric oxygen therapy (HBOT) for any indication at the Hyperbaric Medicine Unit (University Health Network, Toronto, ON, Canada) from 2016-2021 were recruited to this prospective cohort study. While receiving HBOT (at 2.0-2.4 ATA, with 1-3 "air breaks", with specific treatment details determined on a case-by-case basis and directed by the clinical team), enrolled patients underwent pulmonary function testing prior to HBOT treatment and serially after each 20 completed treatment cycles.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsOxygen Toxicity
CountriesCanada
Collaborators--

Timeline

N/ACompletedFinished
20162017201820192020202120222023202420252026
First PostedOct 22, 2021
Enrollment StartFeb 1, 2016
Primary CompletionJun 1, 2021
Study CompletionOct 1, 2022
TodayJul 2, 2026
Enrollment to primary: 5.3 yearsPosted 4.7 years ago

Interventions

Hyperbaric Oxygen Therapydevice

Hyperbaric Oxygen Therapy performed at 100% oxygen at 2.0-2.4 ATA, with 1-3 "air breaks", typically at 5 sessions per week, with limited variation depending on the treatment indication and patient/clinician preference.